Accelerating precision medicine™

Press Release

Wyeth Expands Caprion Biomarker Collaborations to Include Two Clinical Biomarker Programs

Montreal, Canada - June 28, 2005 - Caprion Pharmaceuticals Inc. today announced that Wyeth (NYSE:WYE) has expanded a previously announced collaboration in the discovery and development of protein biomarkers to include two clinical programs currently underway at Wyeth. Wyeth and Caprion had previously and successfully collaborated on preclinical biomarker research in inflammatory disease using CellCarta®, Caprion's proprietary protein expression profiling technology.

The objective of the collaboration is for Caprion to conduct proteomic analyses of human blood plasma samples from patients in two separate phase II clinical trials in the areas of asthma and renal cell carcinoma in order to identify disease state protein biomarkers that may be used in subsequent trials of investigational new drugs.

"This collaboration represents our first example of a pharmaceutical partner expanding its biomarker work with us based on earlier, high-impact studies," noted Lloyd M. Segal, Caprion's President and CEO. "We believe that Wyeth is leading the way in applying the tools of proteomics leaders like us to making better, earlier decisions in the clinical and pre-clinical environment."


About Caprion Pharmaceuticals
Caprion is a leading proteomics-based drug discovery company applying CellCarta® to discover and develop innovative products for the diagnosis and treatment of disease. Caprion has established therapeutic antibody discovery partnerships with Abbott Laboratories (NYSE: ABT) in Lung Cancer, and Biogen IDEC (NASDAQ: BIIB) in Colon Cancer, and pharmaco-proteomic discovery collaborations with Wyeth (NYSE: WYE), AstraZeneca (NYSE: AZN), Merck & Co (NYSE: MRK), and Pfizer (NYSE: PFE). Caprion's partners also include IDEXX Laboratories (NASDAQ: IDXX) and Ortho-Clinical Diagnostics (NYSE:JNJ). Caprion's therapeutic antibodies for the prevention of Hemolytic Uremic Syndrome (HUS) resulting from E. coli infection are currently in Phase I clinical trials. For more on Caprion, see


Caprion Pharmaceuticals
Katherine Bonter
(514) 228-3624

Back to news list